Latest news with #DV
Business Wire
a day ago
- Business
- Business Wire
DoubleVerify Partners with Impact Plus to Help Brands Evaluate The Carbon Footprint of Ad Campaigns
NEW YORK--(BUSINESS WIRE)-- DoubleVerify ('DV') (NYSE: DV), the leading software platform to verify media quality, optimize ad performance, and prove campaign outcomes, today announced a partnership with Impact Plus, a leading sustainability technology company that empowers marketers to reduce the environmental footprint of their advertising. With this release, brands can leverage DV's Emissions Measurement offering powered by Impact Plus, to understand and manage the carbon footprint of their digital advertising campaigns. "As sustainability remains a priority across the advertising ecosystem, brands are looking for ways to understand and address their environmental footprint,' said Steven Woolway, EVP, Business Development at DoubleVerify. 'Our integration with Impact Plus gives advertisers the data and transparency they need to make more informed, responsible decisions without sacrificing performance or scale.' Through a seamless integration, DV's Emissions Measurement, powered by Impact Plus, delivers a clear, end-to-end view of emissions across the entire digital advertising supply chain, enabling brands to evaluate and take action to reduce their carbon impact confidently. Client use cases include: Monitoring and managing emissions: Track and assess the carbon footprint of digital campaigns across the full media supply chain. Benchmarking placements: Compare the carbon efficiency of campaign strategies to inform more sustainable media-buying decisions. Strategic planning: Factor emissions data into campaign planning and optimization to align with internal priorities and business objectives. Unique to DV, later this year, advertisers will be able to leverage DV Scibids AI™, DV's dynamic activation technology, not only to optimize for business outcomes and cost efficiency, but also to shift ad investments toward more eco-friendly placements in real time, helping reduce the environmental impact of their digital campaigns. Impact Plus has developed advanced, automated tools that help advertisers evaluate greenhouse gas (GHG) emissions across campaigns. This integration brings those insights directly into DV's measurement ecosystem, unlocking better decision-making by combining media authentication and carbon impact evaluation. "Reducing advertising's environmental impact starts with evaluation,' said Vincent Villaret, CEO, Impact Plus. 'Together with DoubleVerify, we're helping brands embed sustainability into their digital strategies, making it easier to take action based on GHG emissions and media quality data.' This release reinforces DV's broader commitment to helping advertisers improve media quality and campaign performance while driving more sustainable outcomes at scale. For more information, contact sales@ About DoubleVerify DoubleVerify ('DV') (NYSE: DV) is the industry's leading media effectiveness platform that leverages AI to drive superior outcomes for global brands. By powering media efficiency and performance, DV strengthens the online advertising ecosystem, preserving the fair value exchange between buyers and sellers of digital media. Learn more at About Impact Plus Impact Plus is an award-winning sustaintech solution that enables digital advertising players to evaluate and reduce their environmental impact. Impact Plus builds new performance indicators and solutions to help this ecosystem to use GHG emissions and electricity consumption to inform their digital advertising strategy. A pioneer since 2020, Impact Plus supports brands and their agencies, to enable more sustainable media buying. Impact Plus also enables ad networks and adtech platforms equipping them with environmental impact evaluation solutions, which can be seamlessly integrated into their delivery systems. For more information about Impact Plus, visit
Yahoo
3 days ago
- Business
- Yahoo
2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China evaluating the efficacy and safety of disitamab vedotin (DV), developed by Remegen Co., Ltd., and toripalimab (PD-1) combined with CAPOX or trastuzumab as the first-line therapy for HER2-expressing patients with locally advanced or metastatic (la/m) gastric cancer. Comparing to the control group who received standard-of-care therapy, the DV combination therapy demonstrated clinically meaningful efficacy improvement, potentially to benefit patients who are non-responders to traditional targeted therapies. The data presented are from the Phase 2 part of a randomized, multi-cohort, seamlessly connecting Phase 2/3 study, which enrolled systematic chemotherapy-native patients with different HER2 expression levels. As of April 7, 2025, the results showed: Among HER2-overexpressing gastric cancer patients, compared to the PD-1-trastuzumab-CAPOX combination therapy, DV and PD-1 + chemotherapy as well as DV and PD-1 + trastuzumab both demonstrated statistically significant efficacy and favorable safety profiles. Objective response rate (ORR): 66.7% vs 82.4% vs 68.8%; Median progression-free survival (mPFS): NR vs NR vs 14.1 months, with risk of disease progression decreasing by 54%（HR=0.46）and 41% (HR: 0.59); 12-month PFS rate: 66.3%, 67% and 53.6%； Common TRAEs of grade 3-5: diarrhea, neutrophil count decreased, platelet count decreased, etc. In patients with HER2-low-expressing gastric cancer, promising efficacy was observed with DV + PD-1 + CAPOX comparing to PD-1 + CAPOX, with a manageable safety profile. ORR: 72.0% vs 47.8%; mPFS: 9.9 vs 7.2 months, with risk of disease progression decreasing by 31% (HR: 0.69); Common TRAEs of grade 3-5: diarrhea, neutrophil count decreased, platelet count decreased, etc. Dose optimization conducted in patients with HER2-median/low-expressing gastric cancer. Compared to PD-1 + CAPOX, DV at 2.5 mg/kg or 2.0 mg/kg combined with PD-1 + reduced-dose CAPOX showed significant efficacy, and better safety over the full-dose chemotherapy. ORR: 71.4% vs 66.7% vs 56.3%; 6-month PFS rate: 71.4%，72.7% and 53.3%. Globally, this is the first study to explore the triple combination therapy of "HER2 ADC + PD-1 + targeted medication" as first-line treatment of patients with la/m gastric cancer, pioneering a new mode of synergistic therapy. The multi-cohort design of this study provides precision treatment regimen for gastric cancer patients with different level of HER2 expression. For the HER2-overexpressing gastric cancer patients, DV + PD-1 + trastuzumab has the potential to become the new standard first-line treatment; for the HER2-low-expressing gastric cancer patients, DV + PD-1 + chemotherapy has the potential to fill the treatment gap of these patients. Based on the data obtained from the phase 2 study, the phase 3 clinical study of the triple combination therapy in patients with HER2-median/low-expressing gastric cancer has been initiated in April, 2025, in which 616 participants were planned to be enrolled, to further validate the efficacy of the DV combination therapy. Gastric cancer is the fifth most common malignant tumor in the world, and China accounts for about 42.6% of new cases and 45.0% of deaths worldwide. HER2 is an important target in the treatment of gastric cancer, while the traditional targeted drug trastuzumab is only effective in the population with high expression (IHC 3+ or IHC 2+/FISH+), and can easily become resistant. There is a lack of effective targeted therapy options for patients with low/median HER2 expression (IHC 1+ or IHC 2+/FISH-), and the efficacy of chemotherapy combined with immunotherapy is not satisfactory. As the first domestic HER2-targeted ADC drug in China, DV not only precisely kills tumor cells with HER2 over expression but also attacks adjacent cells with HER2 low expression through the bystander effect. Preclinical studies have also shown that the combination of DV with PD-1 inhibitor and trastuzumab can enhance anti-tumor activity. View original content to download multimedia: SOURCE RemeGen Co., Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
29-05-2025
- Business
- Business Wire
Deadline Approaching: DoubleVerify Holdings, Inc. (DV) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming July 21, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased DoubleVerify Holdings, Inc. ('DoubleVerify' or the 'Company') (NYSE: DV) common stock between , inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN DOUBLEVERIFY HOLDINGS, INC. (DV), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 7, 2024, DoubleVerify released its first quarter 2024 financial results and reduced its 2024 revenue guidance, disclosing that there had been a pullback in customer spending on advertising. On this news, DoubleVerify's stock price fell $11.79, or 38.6%, to close at $18.78 per share on May 8, 2024, thereby injuring investors. Then, on February 27, 2025, DoubleVerify reported lower-than-expected fourth quarter 2024 sales and earnings due in part to reduced customer spending. The Company also disclosed that the shift of ad dollars from open exchanges to closed platforms was having a negative impact on the Company. On this news, DoubleVerify's stock price fell $7.83, or 36%, to close at $13.90 per share on February 28, 2025. Then, on March 28, 2025, Adalytics Research, LLC published a report alleging, among other things, that DoubleVerify's web advertisement verification and fraud protection services were ineffective and that its customers were regularly billed for ad impressions served to bots. The same day, The Wall Street Journal reported that DoubleVerify regularly missed detection of nonhuman traffic despite the Company's claims that it helps brands avoid serving ads to nonhuman bot accounts. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) DoubleVerify's customers were shifting their ad spending from open exchanges to closed platforms, where the Company's technological capabilities were limited and competed directly with native tools provided by platforms like Meta Platforms and Amazon; (2) DoubleVerify's ability to monetize on its Activation Services was limited because the development of its technology for closed platforms was significantly more expensive and time-consuming than disclosed to investors; (3) DoubleVerify's Activation Services in connection with certain closed platforms would take several years to monetize; (4) DoubleVerify's competitors were better positioned to incorporate AI into their offerings on closed platforms, which impaired DoubleVerify's ability to compete effectively and adversely impacted the Company's profits; (5) DoubleVerify systematically overbilled its customers for ad impressions served to declared bots operating out of known data center server farms; (6) DoubleVerify's risk disclosures were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities; and (7) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired DoubleVerify common stock during the Class Period, you may move the Court no later than July 21, 2025 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
27-05-2025
- Business
- Business Wire
Law Offices of Howard G. Smith Encourages DoubleVerify Holdings, Inc. (DV) Investors To Inquire About Securities Fraud Class Action
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased DoubleVerify Holdings, Inc. ('DoubleVerify' or the 'Company') (NYSE: DV) common stock between , inclusive (the 'Class Period'). DoubleVerify investors have until July 21, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN DOUBLEVERIFY HOLDINGS, INC. (DV), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 7, 2024, DoubleVerify released its first quarter 2024 financial results and reduced its 2024 revenue guidance, disclosing that there had been a pullback in customer spending on advertising. On this news, DoubleVerify's stock price fell $11.79, or 38.6%, to close at $18.78 per share on May 8, 2024, thereby injuring investors. Then, on February 27, 2025, DoubleVerify reported lower-than-expected fourth quarter 2024 sales and earnings due in part to reduced customer spending. The Company also disclosed that the shift of ad dollars from open exchanges to closed platforms was having a negative impact on the Company. On this news, DoubleVerify's stock price fell $7.83, or 36%, to close at $13.90 per share on February 28, 2025. Then, on March 28, 2025, Adalytics Research, LLC published a report alleging, among other things, that DoubleVerify's web advertisement verification and fraud protection services were ineffective and that its customers were regularly billed for ad impressions served to bots. The same day, The Wall Street Journal reported that DoubleVerify regularly missed detection of nonhuman traffic despite the Company's claims that it helps brands avoid serving ads to nonhuman bot accounts. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) DoubleVerify's customers were shifting their ad spending from open exchanges to closed platforms, where the Company's technological capabilities were limited and competed directly with native tools provided by platforms like Meta Platforms and Amazon; (2) DoubleVerify's ability to monetize on its Activation Services was limited because the development of its technology for closed platforms was significantly more expensive and time-consuming than disclosed to investors; (3) DoubleVerify's Activation Services in connection with certain closed platforms would take several years to monetize; (4) DoubleVerify's competitors were better positioned to incorporate AI into their offerings on closed platforms, which impaired DoubleVerify's ability to compete effectively and adversely impacted the Company's profits; (5) DoubleVerify systematically overbilled its customers for ad impressions served to declared bots operating out of known data center server farms; (6) DoubleVerify's risk disclosures were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities; and (7) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you purchased DoubleVerify common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
GMA Network
26-05-2025
- Entertainment
- GMA Network
Dina Bonnevie turns vulnerable, admits to missing late husband DV Savellano: 'I long for my husband's embrace'
It's been five months since Dina Bonnevie lost her husband, DV Savellano, and on Instagram Sunday, the actress turned vulnerable and admitted how much she misses him. Posting a reel of their old photos, Dina said, "I long for my husband's embrace; I wish I could tell him everything and he could hold me and wipe away my tears, and protect me and make me feel safe." "I love and miss him so much but I know that he's with Jesus and will always be there to guide me and pray for me," she added, clearly leaning into her faith and putting on a brave face. According to Dina, so much has changed since DV passed away in January. "Death is indeed an eye opener," she said. In the comment section of her post, friends including Geneva Cruz, Aiko Melendez, and Eula Valdez expressed their support for Dina. DV, an undersecretary at the Department of Agriculture, passed away due to an abdominal aneurysm. He was laid to rest in Cabuyao. Following his death, Dina also took to Instagram to admit his death was the most painful and most traumatic experience she's ever had to go through. — LA, GMA Integrated News
